INTRODUCTION {#s1}
============

As one of the most common malignances, gastric cancer (GC)is nowadays the secondary leading cause of cancer-related mortality in China, in spite of a declining global incidence \[[@R1]\]. The identification of its prognostic factors becomes of great importance for the survival prediction of gastric cancer patients. Currently, tumor-node-metastasis (TNM) staging system, as the most commonly used staging system for gastric cancer, is applied both in the Japanese Gastric Cancer Association (JGCA) \[[@R2]\] and the American Joint Committee on Cancer (AJCC) \[[@R3]\], not only because of its discriminatory power on the prognostic difference but also due to its predictive accuracy. However, it requires examining at least 15 lymph nodes to make N staging adequately and accurately, which has limited its use in clinical practice. Fortunately, node ratio (Nr), defined as the ratio of the positive lymph nodes to the retrieved lymph nodes, needless of considering the number of retrieved lymph nodes, which was regarded as an alternative system to N staging system, has been identified as an important independent prognostic factor in majority of studies \[[@R4]--[@R12]\]. Nevertheless, these findings are not universally supported \[[@R13], [@R14]\], and Nr has not yet been integrated into the current staging system for gastric cancer up till now. Thus, the controversy for the prognostic significance of Nr still remains.

In light of these considerations mentioned above, we performed this study to evaluate the prognostic significance of node ratio (Nr), and to investigate whether a modified staging system, TNrM which is based on Nr, can improve prognostic discriminatory ability and predictive accuracy for gastric cancer patients undergoing gastrectomy.

RESULT {#s2}
======

Correlation analysis between the clinicopathologic factors and node ratio {#s2_1}
-------------------------------------------------------------------------

X-tile plots, constructed in Figure [1](#F1){ref-type="fig"}, illustrated that the optimal cutoff points for node ratio (Nr) were 0.15 and 0.40 in node-positive patients using minimum *P* value from log-rank χ^2^ test, according to which patients were categorized into four groups, Nr0:0.0 Nr1:0.0-0.15, Nr2:0.15-0.40, Nr3: \> 0.40, with the strongest discriminatory capacity.

![Division of patients by the cutoff points produced by X-tile plot\
(**A**) X-tile plots for lymph node ratio (Nr). The plots illustrate that the produced log-rank χ^2^ value stratify the node-positive patients into 3 groups by two cutoff points, 0.15 and 0.40. (**B**), survival curves generated by X-tile plots, show a strong discriminatory capacity, with a χ^2^ value of 156.7 and a relative risk ratio of 1.00/1.53/2.32.](oncotarget-07-51069-g001){#F1}

Clinicopathologic factors were compared between the training set and validation set, and among the four groups, as shown in Table [1](#T1){ref-type="table"}. There was no significant difference between the training set and validation set regarding all the clinicopathologic factors (all the *p***\*** value \> 0.05), which meant that the baseline was balanced between them. Besides, both in the training and validation set, Nr stage was found to be significantly associated with macroscopic type, tumor differentiation, lymphovascular invasion, perineural invasion, tumor size, T stage, N stage and TNM stage (all the *p* value \< 0.05). However, no significance was found between Nr and age, gender as well as adjuvant chemotherapy. There were significantly more patients with macroscopic type III-IV, poorly tumor differentiation, positive lymphovascular/perineural invasion, larger tumor size and advanced TNM stage in higher node ratio stages (Nr2 and Nr3) than that in lower node ratio stages (Nr0 and Nr1).

###### Patients and clinicopathologic factors

                            Training set   Validation set   P\*                                                                 
  ------------------------- -------------- ---------------- ----- ----- ------ ---------- ----- ---- ---- ---- ----- ---------- -------
  Gender                                                                       0.172                                 0.248      0.051
   Male                     501            308              361   333   1503              103   75   71   67   316              
   Female                   200            133              123   144   600               54    40   38   24   156              
  Age (years)                                                                  0.067                                 0.131      0.059
   ≥ 60                     308            213              209   194   924               73    57   48   52   230              
   \< 60                    393            228              272   286   1179              84    58   61   39   242              
  Tumor location                                                               0.152                                 0.245      0.112
   Upper third              175            104              128   117   524               39    20   25   19   103              
   Middle third             155            96               96    119   466               38    39   29   22   128              
   Lower third              357            232              253   230   1072              77    55   53   46   231              
   ≥ 2/3 stomach            14             9                7     11    41                3     1    2    4    10               
  Macroscopic type                                                             \< 0.001                              \< 0.001   0.069
   Borrmann 0--II           395            284              280   225   1184              85    83   59   17   244              
   Borrmann III-- IV        306            157              204   252   919               72    32   50   74   228              
  Tumor differentiation                                                        \< 0.001                              \< 0.001   0.141
   Well/Moderately          138            124              96    56    414               30    25   16   8    79               
   Poorly                   563            317              388   421   1689              127   90   93   83   393              
  Lymphovascular invasion                                                      0.008                                 0.003      0.083
   Negative                 437            292              305   275   1311              90    82   60   42   274              
   Positive                 264            147              179   202   792               67    33   49   49   198              
  Perineural invasion                                                          0.004                                 \< 0.001   0.054
   Negative                 560            374              377   368   1679              121   91   69   67   358              
   Positive                 141            67               107   109   424               36    14   40   24   114              
  Adjuvant chemotherapy                                                        0.087                                 0.271      0.090
   Present                  254            181              195   207   837               47    45   44   32   168              
   Absent/Unclear           447            260              299   270   1266              110   70   65   59   304              
  Tumor size                                                                   \< 0.001                              \< 0.001   0.102
   ≤ 4.5 cm                 234            191              178   99    702               51    54   49   17   171              
   4.5-7.5 cm               330            188              230   241   989               71    49   43   33   196              
   ≥ 7.5 cm                 137            62               73    140   412               35    12   17   41   105              
  Retrieved lymph nodes                                                        0.901                                 0.900      0.121
   ≥ 15                     499            323              348   342   1512              119   87   84   66   356              
   \< 15                    202            118              136   135   591               38    28   25   25   116              
  T Stage                                                                      \< 0.001                              \< 0.001   0.097
   T1                       42             52               27    6     127               13    17   3    6    39               
   T2                       81             74               60    28    243               22    29   13   2    66               
   T3                       57             54               41    19    171               10    7    7    6    30               
   T4a                      435            229              309   331   1304              91    57   79   63   290              
   T4b                      86             32               47    93    258               21    5    7    14   47               
  N Stage                                                                      \< 0.001                              \< 0.001   0.194
   N0                       701            0                0     0     701               157   0    0    0    157              
   N1                       0              316              68    21    405               0     75   16   15   106              
   N2                       0              119              216   84    419               0     26   46   3    75               
   N3a                      0              6                184   215   405               0     11   43   35   89               
   N3b                      0              0                16    157   173               0     3    4    38   45               
  TNM Stage                                                                    \< 0.001                              \< 0.001   0.066
   IA                       290            0                0     0     290               51    0    0    0    51               
   IB                       129            50               11    2     192               35    10   7    2    54               
   IIA                      101            64               22    3     190               25    10   3    2    40               
   IIB                      92             47               36    12    187               25    9    8    4    46               
   IIIA                     82             171              79    37    369               20    66   6    11   103              
   IIIB                     7              92               167   75    341               1     17   48   12   78               
   IIIC                     0              17               169   348   534               0     3    37   60   100              

Identification of risk factors and multicollinearit analysis for node ratio {#s2_2}
---------------------------------------------------------------------------

As illustrated in Table [2](#T2){ref-type="table"}, logistic regression analysis was performed to determine the risk factors for Nr. In the univariate analysis, the involved factors significantly consisted of clinicopathologic factors, such as age (OR = 1.165, *p* = 0.022), tumor location (OR = 0.382, *p* = 0.003), macroscopic type (OR = 1.430, *p* \< 0.001), tumor differentiation (OR = 1.697, *p* \< 0.001), lymphovascular invasion (OR = 1.436, *p* = 0.023), perineural invasion (OR = 1.037, p = 0.052), tumor size (OR = 1.541, *p* = 0.011), T stage (OR = 1.234, *p* = 0.023) and N stage (OR = 3.812, *p* \< 0.001). Multivariate logistic regression model analysis indicated that tumor differentiation (OR = 1.045, *p* = 0.010), lymphovascular invasion (OR = 1.011, *p* = 0.045) and N stage (OR = 2.631, *p* \< 0.001) were independent risk factors for Nr.

###### Logistic regression analysis of the risk factors for node ratio (Nr)

  Factors                   Univariate analysis    Multivariate analysis                          
  ------------------------- ---------------------- ----------------------- ---------------------- ----------
  Gender                    1.004 (0.758--1.332)   0.187                   \-                     \-
  Age                       1.165 (1.022--1.328)   0.022                   0.856 (0.640--1.146)   0.244
  Tumor location            0.382 (0.202--0.723)   0.003                   1.020 (0.861--1.208)   0.973
  Macroscopic type          1.430 (1.252--1.633)   \< 0.001                0.807 (0.602--1.082)   0.277
  Tumor differentiation     1.697 (1.433--2.010)   \< 0.001                1.045 (1.008--1.321)   0.010
  Lymphovascular invasion   1.436 (1.115--1.798)   0.023                   1.011 (1.002--1.230)   0.045
  Perineural invasion       1.037 (0.931--1.041)   0.052                   \-                     \-
  Adjuvant chemotherapy     0.843 (0.665--1.210)   0.310                   \-                     \-
  Tumor size                1.541 (1.326--1.791)   0.011                   0.903 (0.667--1.221)   0.507
  Retrieved lymph node      0.923 (0.771--1.132)   0.123                   \-                     \-
  T Stage                   1.234 (1.012--1.991)   0.023                   1.085 (0.910--1.236)   0.064
  N Stage                   3.812 (2.467--4.943)   \< 0.001                2.631 (1.912--3.676)   \< 0.001

OR: Odds Ratio; CI: Confidence Interval.

In order to assess the multicollinearity between Nr and these independent factors identified above, spearman correlation analyses were performed in Table [3](#T3){ref-type="table"}, demonstrating that N stage was correlated with Nr (*r* = 0.724, *p* \< 0.001), while tumor differentiation, lymphovascular invasion and T stage showed no correlation with Nr (all the *r* value \< 0.3). Additionally, scatter spots in Figure [2](#F2){ref-type="fig"}, suggested that there was positive linear correlation between the number of positive lymph node and Nr (*R* ^2^ = 0.457).

###### Spearman correlation analysis of the multicollinearity for node ratio (Nr)

  Factors                   Correlation coefficient (r)                *P* value
  ------------------------- ------------------------------------------ -----------
  Tumor differentiation     0.166[\*](#tfn_001){ref-type="table-fn"}   \< 0.001
  Lymphovascular invasion   0.214[\*](#tfn_001){ref-type="table-fn"}   \< 0.001
  T Stage                   0.290[\*](#tfn_001){ref-type="table-fn"}   \< 0.001
  N Stage                   0.724[\*](#tfn_001){ref-type="table-fn"}   \< 0.001

Correlation is significant at the 0.01 level (2 tailed);

r: correlation coefficient; \|r\| \< 0.3: no correlation; 0.3 ≥ \|r\|: correlation exists.

![Positive linear correlation between the number of positive lymph node and Nr (R^2^ = 0.457) in scatter spots](oncotarget-07-51069-g002){#F2}

Univariate and multivariate analyses of factors associated with patients\' prognosis {#s2_3}
------------------------------------------------------------------------------------

As shown in Table [4](#T4){ref-type="table"}, the 5-year overall survival rates (5-y OS) for these four Nr stages were 72.5%, 63.4%, 46.9% and 22.6%, respectively, whereas the 5-y OS for different TNrM stages were 82.5%, 80.8%, 73.4%, 61.8%, 57.0%, 41.3% and 22.4%, respectively. Univariate analysis with cox regression model in Table [5](#T5){ref-type="table"} showed clinicopathologic factors, including gender, age, macroscopic type, tumor differentiation, lymphovascular invasion, perineural invasion, adjuvant chemotherapy, tumor size, T stage and N stage as well as Nr stage, were significant prognostic factors for patients. However, multivariate analysis indicated that only age (HR = 0.751, *p* \< 0.001), tumor size (HR = 1.181, *p* = 0.006), T stage (HR = 1.271, *p* \< 0.001), N stage (HR = 1.209, *p* = 0.003) and Nr stage (HR = 1.413, *p* \< 0.001) were independent prognostic factors for gastric cancer patients, after adjustment of the confounding factors.

###### Prognostic prediction by Kapplan--Meier survival analyses

  Factors      3--year OS (%)   5--year OS (%)   MS (months)          AIC     C--index   Log rank χ^2^ value   *P*
  ------------ ---------------- ---------------- -------------------- ------- ---------- --------------------- ----------
  N stage                                                             898.7   0.687      151.1                 \< 0.001
  N0           85.2             72.5             124.1 (7.5--176.0)                                            
  N1           76.1             63.4             113.0 (3.5--174.0)                                            
  N2           67.1             52.8             99.5 (1.4--172.4)                                             
  N3a          42.3             27.5             29.9 (0.9--160.0)                                             
  N3b          26.5             20.4             23.0 (0.3--172.7)                                             
  Nr stage                                                            880.1   0.696      156.7                 \< 0.001
  Nr0          85.2             72.5             124.1 (7.5--176.0)                                            
  Nr1          78.3             63.4             106.0 (1.4--160.0)                                            
  Nr2          58.4             46.9             54.9 (0.3--174.0)                                             
  Nr3          30.4             22.6             26.1 (0.9--172.7)                                             
  TNM stage                                                           872.3   0.754      161.7                 \< 0.001
  IA           92.6             82.5             134.2 (9.3--156.2)                                            
  IB           87.3             77.2             121.2 (1.4--172.4)                                            
  IIA          81.1             71.6             101.3 (0.3--174.0)                                            
  IIB          79.8             60.6             92.7 (4.0--176.0)                                             
  IIIA         66,2             55.4             82.6 (5.4--157.2)                                             
  IIIB         55.9             46.2             46.6 (0.9--150.3)                                             
  IIIC         33.1             22.2             25.4 (0.8--172.7)                                             
  TNrM stage                                                          850.4   0.799      182.3                 \< 0.001
  IA           92.6             82.5             134.2 (9.3--165.2)                                            
  IB           90.4             80.8             112.5 (6.5--176.0)                                            
  IIA          85.0             73.4             98.4 (1.4--160.9)                                             
  IIB          79.5             61.8             84.6 (0.3--173.1)                                             
  IIIA         64.3             57.0             65.4 (0.8--161.8)                                             
  IIIB         56.4             41.3             47.3 (0.9--175.6)                                             
  IIIC         30.2             22.4             24.0 (0.6--172.3)                                             

OS: overall survival ; MS: median survival time; AIC: Akaike Information Criterion value; C--index: concordance index.

###### Univariate and multivariate analyses of the patients\' clinicopathologic factors by Cox regression model

  Factors                   Univariate analysis    Multivariate analysis                          
  ------------------------- ---------------------- ----------------------- ---------------------- ----------
  Gender                    0.825 (0.691--0.984)   0.033                   0.808 (0.732--1.091)   0.301
  Age                       0.744 (0.637--0.869)   \< 0.001                0.751 (0.611--0.881)   \< 0.001
  Tumor location            0.933 (0.852--1.022)   0.138                   --                     --
  Macroscopic type          1.329 (1.137--1.553)   \< 0.001                1.016 (0.872--1.221)   0.754
  Tumor differentiation     1.109 (1.032--1.257)   0.041                   1.012 (0.819--1.273)   0.288
  Lymphovascular invasion   1.246 (1.129--1.478)   \< 0.001                1.138 (0.932--1.431)   0.064
  Perineural invasion       1.051 (1.002--1.171)   0.087                   --                     --
  Adjuvant chemotherapy     1.244 (1.112--1.653)   0.032                   1.104 (0.912--1.412)   0.136
  Tumor size                1.682 (1.461--1.796)   \< 0.001                1.181 (1.041--1.353)   0.006
  Retrieved lymph node      0.893 (0.652--1.012)   0.211                   --                     --
  T stage                   1.539 (1.404--1.686)   \< 0.001                1.271 (1.151--1.423)   \< 0.001
  N stage                   1.593 (1.473--1.723)   \< 0.001                1.209 (1.013--1.389)   0.003
  Nr stage                  1.856 (1.674--2.056)   \< 0.001                1.413 (1.147--1.698)   \< 0.001

HR: Hazard Ratio; CI: Confidence Interval; -- :not enter the regression model.

Comparison and validation of different staging systems {#s2_4}
------------------------------------------------------

Akaike information criterion (AIC) and concordance index (C-index) values for each staging system in Table [4](#T4){ref-type="table"} were calculated to evaluate the prognostic discriminatory ability and predictive accuracy, respectively. Compared with N staging system, Nr staging system had a smaller AIC value and a larger C-index (*p* \< 0.05, Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), indicating that Nr stage was advantageous to N stage in survival prediction discriminatory ability and accuracy. In addition, TNrM staging system was found to be with a larger C-index and a smaller AIC than that of current TNM staging system (*p* \< 0.05), and overlapping curves were found in the TNM staging system but not in the TNrM staging system (Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}), with no significant difference on survival between stage IA and IB (*p* = 0.340), stage IB and stage IIA (*p* = 0.116), stage IIA and IIB (*p* = 0.080) existing in the current TNM staging system, which illustrated that TNrM staging system had a better discriminatory ability and accuracy than that of TNM staging system in prognostic prediction. In the subgroup analysis, for patients with retrieved lymph nodes \< 15, Nr staging system (AIC = 883.2; C-index = 0.683) suggested significant improvement than N staging system (AIC = 889.7; C-index = 0.603) (*p* \< 0.05, Figure [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}), whereas no significant difference was found between Nr and N staging system in patients with retrieved lymph nodes ≥15 in prognostic discriminatory ability and predictive accuracy (*p* \> 0.05, Figure [4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

![Comparative survival analysis on discriminatory ability and accuracy\
(**A**), survival curves of patients according to subgroups of N stage. (**B**), survival curves of patients according to subgroups of Nr stage. (**C**), survival curves of patients according to subgroups of TNM stage. (**D**), survival curves of patients according to subgroups of TNrM stage. The significance of difference between survival curves was calculated by the log-rank test.](oncotarget-07-51069-g003){#F3}

![Stratified comparative survival analysis on discriminatory ability and accuracy according to the different number of retrieved lymph nodes\
(**A**, **B**): survival curves of patients with retrieved lymph node ≥ 15 in terms of subgroups of N and Nr stage. (**C**, **D**): survival curves of patients with retrieved lymph node \< 15 in terms of subgroups of N and Nr stage. The significance of difference between survival curves was calculated by the log-rank test.](oncotarget-07-51069-g004){#F4}

We also respectively applied the Nr and TNrM staging system in the validation set, found that the results were as same as that in the training set: both of Nr and TNrM staging revealed significant superiority to their counterparts, N and TNM staging system. Furthermore, nomograms were used to predict 5-year OS of patients. Both in the training set and validation set, Nr was selected as an independent prognostic factor in nomograms (Figure [5A](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}), which was similar to those of aforementioned multivariate analysis by cox regression. Moreover, corresponding calibration curves in the two sets suggested that the predictive probability of 5-year survival were closely to the actual 5-year survival t (Figure [5B](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}).

![Nomogram plots and calibration curves based on Nr stage\
(**A**, **B**): nomogram plots and calibration curves in the training set. (**C**, **D**): nomogram plots and calibration curves in the validation set.](oncotarget-07-51069-g005){#F5}

In order to evaluate how much improvement was gained using the cutoff points in this study, we also validated the different cutoff points reported in previous studies to create several predictive staging systems, generating various AIC values and C-indexes, as shown in Table [6](#T6){ref-type="table"}. We furtherly compared them to the AIC and C-index produced in our study, and found that the cutoff points, 0, 0.15, 0.40, in our study, had a larger C-index and a smaller AIC value than those produced in previous studies (all *p* \< 0.05, Table [6](#T6){ref-type="table"}), illustrating the cutoff points produced in our study using X-tile were the optimal ones.

###### Comparison and validation of different cutoff points for Nr

  Authors (ref.)           Cutoff points             AIC      C-index   *P*
  ------------------------ ------------------------- -------- --------- ---------
  Melis et al \[[@R5]\]    0,0.30,0.60               892.1    0.701     \< 0.05
  Deng et al \[[@R8]\]     0,0.13,0.80               900.3    0.698     \< 0.01
  Zeng et al \[[@R16]\]    0,0.50,0.80               912.4    0.674     \< 0.05
  Wang et al \[[@R10]\]    0,0.067, 0.30,0.70        886.9    0.712     \< 0.05
  Lee et al \[[@R23]\]     0,0.05, 0.10,0.20, 0.30   998.8    0.675     \< 0.05
  Zhang et al \[[@R18]\]   0,0.10,0.25               1012.7   0.602     \< 0.01
  Wu et al \[[@R6]\]       0,0.20,0.50               862.5    0.772     \< 0.05
  Kutlu et al \[[@R9]\]    0,0.20,0.50               862.5    0.772     \< 0.05
  Zhou et al \[[@R11]\]    0,0.20,0.50               862.5    0.772     \< 0.05
  Wong et al \[[@R17]\]    0,0.20,0.50               862.5    0.772     \< 0.05

DISCUSSION {#s3}
==========

Although a great many studies, evaluating the prognostic significance of Nr in patients with gastric cancer, illustrated that Nr was an independent predictor and more emphases should be put on it, no agreement has been reached yet by far, due to the limitation of different cutoff points and evaluation criteria \[[@R4]--[@R11], [@R15]--[@R17]\]. Particularly, there existed no unified and well-recognized cutoff points for Nr in gastric cancer. In this present study, we applied three cutoff points: 0, 0.15, 0.40, produced by X-tile, which demonstrated better discriminatory ability and more predictive accuracy than those proposed in previous studies, and found that patients with larger Nr were companied by worse biological behavior as well as more aggressive features than patients with smaller Nr, both in the training and validation set.

Specifically, patients with larger Nr were found more frequently with the presence of advanced macroscopic type, poorly tumor differentiation, positive lymphovascular/perineural invasion, larger tumor size and deeper tumor invasion as well as wider lymph nodes metastasis. Besides, logistic regression analysis in our study showed that tumor differentiation, lymphovascular invasion and N stage were independent risk factors for Nr, suggesting that these three factors were closely associated with Nr and multicollinearity might exist between them. However, only Nr was confirmed to be positively correlated with N stage in spearman analysis, being consistent with previous studies \[[@R11], [@R14], [@R18]\], which was the reason why we substituted N with Nr in the current TNM staging system to come up with a modified staging system, TNrM.

We also focused on the prognostic significance of Nr. Apart from age, tumor size, T stage and N stage, Nr stage was illustrated to be independent prognostic factors for gastric cancer patients in multivariate Cox regression analysis. Comparison analysis on survival prediction illustrated that Nr staging system had a better discriminatory prognostic ability and a more predictive accuracy than that of N staging system. Although our findings were consistent with the majority of studies \[[@R6]--[@R9]\], Espin et al concluded that, Nr stage showed no improvement in predictive accuracy than N stage, despite that Nr and N stage were both demonstrated to be independent prognostic factors \[[@R14]\], which was due to the consideration that the proportion of patients with retrieved lymph nodes ≥ 15 in our study was not so much as that in Espin\'s study. Besides, nomogram, was also applied in our study to demonstrate the prognostic significance of independent factors on gastric cancer patients. Both in the training and validation set, the predictive accuracy of nomogram based on Nr was well demonstrated through calibration curves. But, we found that Nr but not N stage was included in the nomogram, which might due to the consideration that, Nr and N were both essential variables reflecting tumor biological features and interactive confounding effect like positive linear correlation existed between them. Moreover, taking the place of N stage in TNM staging system, Nr presented powerful survival discrimination for gastric cancer patients.

A good staging system, which is of great importance for gastric cancer patients in clinical practice, should be able to distinguish the survival difference among several subgroups of patients, and to provide accurate prognostic estimation and beneficial guidance of selecting appropriate adjuvant therapy \[[@R19]\]. As an powerful independent prognostic factor, the N stage in the current TNM staging system is based on the number of metastatic lymph nodes, regardless of the total number of retrieved lymph nodes in surgery. However, the prognosis of gastric cancer patients will be underestimated because of inappropriate staging in case of insufficient retrieved number of lymph nodes, especially when less than 15 lymph nodes are examined. The current TNM staging system was reported not to be an independent prognostic factor for the patients with retrieved lymph nodes fewer than 15 in a study from memorial sloan Kettering cancer Center \[[@R20]\]. Besides, the "stage migration" phenomenon could be observed in about 15% of patients with gastric cancer using the current TNM staging system \[[@R21]\]. Consequently, the prognostic value of N stage is questioned by many oncologists in light of these shortcomings mentioned above, and Nr, defined as the ratio of the metastatic lymph node to the total number of retrieved lymph nodes, regardless of lymph nodes number, is considered as an alternative option. In this present study, Nr stage was shown to have better discriminatory ability and more accurately prediction than N. Although there was no predictive difference for patients with retrieved lymph nodes ≥ 15, Nr stage revealed superiority in survival prediction for patients with retrieved lymph nodes \< 15, demonstrating that Nr stage would better compensate for N stage shortcomings in gastric cancer patients, which is consistent with previous studies \[[@R10], [@R22], [@R23]\]. Additionally, a modified staging system, TNrM staging system based on Nr stage, predicted more accurately on overall survival by comparison of the current TNM staging system according to the findings in our study (Figure [3](#F3){ref-type="fig"}), which was consistent with the findings mentioned in previous investigations \[[@R6], [@R11], [@R16], [@R17], [@R24]\]. To show the improvement we got in this study, we also validated the various cutoff points produced in previous studies, which was not commonly done by previous authors, and found that the Nr stage, categorized by our cutoff points: 0, 0.15, 0.40 could produce the best prognostic discriminatory ability and predictive accuracy.

There were also some limitations in our study. First of all, our findings we got were just on the basis of a non-randomized retrospective single-center study, which might be observed by chance in spite of the large sample. In addition, there might be various perioperative treatment of patients which could affect the survival and interfere the evaluation of the prognostic factors, especially the preoperative therapy may lead to the downstage of the gastric cancer and that is why these patients were excluded in this study. Therefore, multicenter investigations are needed to evaluate the TNrM staging system can whether be superior to TNM staging system for the GC patients before stronger statement can be done.

In conclusion, Nr could be considered as a reliable prognostic factor, even in patients with insufficient (\< 15) retrieved lymph nodes, and TNrM staging system may improve the prognostic discriminatory ability and accuracy for gastric cancer patients undergoing radical gastrectomy, which should be superior to the current TNM staging system.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

The West China Hospital Research Ethics Committee approved the retrospective analysis of anonymous data. Patient records were anonymized and de-identified prior to analysis, and signed patient informed consent was waived because of the retrospective nature of the analysis.

A total of 3115 consecutive GC patients who received gastrectomy in West China Hospital from January 2000 to March 2011, were retrospectively evaluated in this study. The diagnosis of primary gastric cancer for all patients was confirmed by upper gastrointestinal endoscopy and biopsy. Patients were excluded on the condition that: (1) patients who underwent palliative surgery with positive residual margins; (2) with any pre-operative chemotherapy or radiotherapy; (3) with multiple stomach tumors; (4) with another malignancy or any other life-threatening diseases diagnosed during three years prior to the operation; (5) with death due to postoperative complications in hospital; (6) with surgical findings of distant metastasis or peritoneal dissemination, or distant metastatic lymph nodes defined as M1 in JGCA \[[@R2]\]. Finally, 2575 patients were enrolled in this study as shown in Figure [6](#F6){ref-type="fig"} and 2305 of these patients were followed up (89.50%). Patients were randomly divided into two sets using X-tile with the ratio of 4.5:1, among which 2103 patients were used as the training set, whereas 472 patients were regarded as the validation set.

![The flow chart of patients enrolled in this study](oncotarget-07-51069-g006){#F6}

The clinicopathologic characteristics including of gender, age, tumor location, macroscopic type, tumor differentiation, lymphovascular invasion, perineural invasion, postoperative adjuvant chemotherapy, tumor size, number of retrieved lymph node, T stage, N stage, TNM stage evaluated according to 7^th^ edition of AJCC TNM staging system \[[@R3]\] and follow-up information were collected.

Definition of Nr and TNrM staging system {#s4_2}
----------------------------------------

On the basis of cutoff points determined by X-tile, node ratio (Nr), the ratio between the absolute number of metastatic lymph node and the total number of lymph nodes retrieved at the time of gastric resection, was divided into four groups: Nr0 (Nr = 0.0), Nr1 (Nr:0.0--0.15), Nr2 (Nr:0.15--0.40), Nr3 (Nr ≥ 0.40), defined as Nr stage, corresponding to N0, N1, N2 and N3, respectively, in N stage. Therefore, we substituted N stage with Nr stage in TNM staging system, forming a new staging system, TNrM staging system, which was regarded as combination of T stage, Nr stage and M stage.

Statistical analysis {#s4_3}
--------------------

X-tile program (Version 3.1.2, Yale University) was used to calculate the optimal cutoff points for Nr using minimum *P* value from log-rank χ^2^ statistics, because that it does not only play a crucial role in complicated cutoff point selection but also can randomly divide a single cohort into training set and validation set \[[@R25]\]. Mann-Whitney U test in the SPSS version 19.0 was applied to evaluate ranked variables, while Chi-square test was performed to analyze unordered categorical variables. Logistic regression analysis was used to analyze risk factors for Nr, whereas spearman correlation analysis was applied to evaluate the multicollinearity. Cox\'s proportional hazard regression model with conditional backward stepwise was displayed to univariate and multivariate survival analyses. The cumulative survival rates were calculated using the Kaplan-Meier method and life-table in the SPSS version 19.0, with subgroups compared by the log-rank test through GraphPad Prism 5. Nomogram and calibration curve were displayed using the package of Regression Modeling Strategies *(URL [http://CRAN.R-project.org/package=rms](http://cran.r-project.org/package=rms))* in R (version3.1.2.*URL [http://www.R-project.org/](http://www.r-project.org/).*) Comparisons between the different staging systems for the prognostic prediction were conducted with the package of Harrell Miscellanceous *(URL [http://CRAN.R-project.org/package=Hmisc](http://cran.r-project.org/package=Hmisc).)*, in which Akaike information criterion (AIC) and concordance index (C-index) values within a cox proportional hazard regression model were calculated for each staging system to measure their discriminatory ability and accuracy, respectively. A smaller AIC valueindicated a better model for predicting outcome \[[@R8]\], whereas a larger C-index demonstrated a more accurate prognostic prediction \[[@R26]\]. The two-sided *p* value of less than 0.05 was considered to be statistically significant.
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